Evaluating TACE Outcomes in HCC Patients

Patients diagnosed with HCC and underwent TACE from January 2008 to December 2019 were included and analyzed. The inclusion criteria were as follows: (1) age greater than 18 years; (2) HCC diagnosis by imaging or histological findings according to the American Association for the Study of Liver Disease guidelines^{15 (link)}; (3) initial treatment with conventional TACE; (4) HCC with Barcelona Clinic Liver Cancer (BCLC) stage A, B, or C (subsegmental or segmental portal vein tumor thrombosis); (5) available medical records; and (6) Child–Pugh class A or B. The exclusion criteria were as follows: (1) absence of imaging data; (2) inability to measure the skeletal muscle mass; (3) concomitant malignancies; and (4) history of HCC rupture.